Table 2.
Additional 201 analyzed genes significantly associated with OC risk in the group of all OC patients and in a subgroup of 934 patients without mutations in 10 established OC predisposition genes.
| Gene | Patients N Mutations (%) | 2278 PMC N Mutations (%) | OR (95% CI); p (Bonferroni Corrected p) |
|---|---|---|---|
| All 1333 OC patients | |||
| PPM1D | 16 (1.20) | 2 (0.09) | 13.82 (3.24–124.22); 7.4 × 10−6 (0.001) |
| NAT1 | 13 (0.98) | 5 (0.22) | 4.48 (1.49–16.07); 0.003 (n.s.) |
| SHPRH | 5 (0.38) | 1 (0.04) | 8.57 (0.96–404.83); 0.028 (n.s.) |
| 934 OC patients without mutations in 10 genes significantly associated with OC in our study | |||
| PPM1D | 12 (1.28) | 2 (0.09) | 14.80 (3.28–136.67); 1.7 × 10−5 (0.003) |
| NAT1 | 8 (0.86) | 5 (0.22) | 3.96 (1.13–15.30); 0.026 (n.s.) |
| MMP8 | 6 (0.64) | 4 (0.18) | 3.67 (0.87–17.74); 0.041 (n.s.) |
| FANCG | 5 (0.53) | 2 (0.09) | 6.12 (1.00–64.45); 0.025 (n.s.) |
n.s., nonsignificant.